Eli Lilly and Company (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) have taken their fierce rivalry from pharmacy shelves to a federal courtroom in New Jersey.
Novo Nordisk filed suit against Eli Lilly on July 21, accusing its primary rival of false advertising and unfair competition tied to television and digital campaigns for Zepbound and Mounjaro.
At the heart of Novo Nordisk’s legal complaint is its claim that Lilly’s promotional campaigns deliberately use outdated trial data to compare tirzepatide’s highest approved doses against lower, older doses of semaglutide.
Novo Nordisk argues that these advertisements omit its recently approved higher-dose versions, creating consumer confusion, and is demanding a permanent injunction alongside a corrective advertising campaign.
Eli Lilly fired back immediately, stating that its commercials are “truthful,” “transparent,” and grounded in direct scientific evidence from the SURMOUNT-5 head-to-head clinical trial comparing tirzepatide against semaglutide.
Lilly accused Novo Nordisk of attempting to censor published trial results rather than compete on product merits, and confirmed it intends to defend itself “vigorously” in court.
Beyond the courtroom dispute, Eli Lilly’s Q1 2026 financial results show the company pulling decisively ahead, with revenue surging 56% year-over-year to $19.8 billion, driven by a 65% increase in sales volume.
Net income at Lilly reached $7.4 billion, or $8.26 per share, compared with $2.8 billion, or $3.06 per share, in Q1 2025, while non-GAAP EPS surged 156% to $8.55, reflecting strong operating leverage.
Backed by accelerating demand, Eli Lilly raised its full-year 2026 revenue guidance by $2 billion, lifting the expected range to $82.0 billion to $85.0 billion and its non-GAAP EPS outlook to $35.50 to $37.00.
Novo Nordisk posted net sales growth of 32% year-over-year in constant exchange rates to DKK 96.82 billion, equivalent to approximately $13.8 billion, though the headline figure was inflated by a $4.2 billion non-recurring provision reversal.
Excluding that one-time benefit, Novo Nordisk’s adjusted sales actually declined 4% at constant exchange rates, reflecting ongoing pricing pressure in the U.S. market despite continued GLP-1 volume growth.
Adjusted operating profit at Novo Nordisk declined 6% at constant exchange rates to DKK 32.86 billion, underscoring margin headwinds that contrast sharply with Lilly’s expanding profitability.
Novo Nordisk did advance its obesity franchise during the quarter, recording DKK 2.26 billion in Q1 revenue from the U.S. launch of the oral Wegovy pill and securing FDA approval for the Wegovy HD 7.2 mg injection.
The newly approved Wegovy HD demonstrated nearly 21% mean weight loss in clinical trials, providing Novo Nordisk with a stronger competitive footing as it works to close the clinical gap with tirzepatide.
Institutional positioning data from Insider Monkey shows that hedge fund conviction is diverging sharply, with 132 funds holding Eli Lilly shares in Q1 2026 compared to just 55 funds holding Novo Nordisk positions.
Among notable Lilly holders, Bourgeon Capital, managed by John Zaro, increased its position by 5% to 24,426 shares valued at $29.30 million, representing 4.31% of its portfolio.
HealthInvest Partners AB, managed by Anders Hallberg and Carl Bennet, holds 29,821 Lilly shares valued at $35.77 million, representing 9.62% of the fund’s portfolio despite a 25% trim in the period.
Novo Nordisk’s hedge fund footprint remained flat at 55 funds across both Q4 2025 and Q1 2026, with notable positions including Taproot Management, led by David Lin and Jason Beverage.
As supply constraints ease for both companies, the longer-term competitive battle will likely hinge on who delivers next-generation oral weight-loss formulations to market first, rather than on courtroom outcomes over advertising disclosures.
For now, Eli Lilly holds a clear advantage across clinical efficacy data, U.S. commercial momentum, revenue growth rate, and institutional investor confidence in the global obesity treatment market.
